Mauro Delorenzi

Medicine · Health Sciences

85h-index42.1kcitations437works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(104), Genetic factors in colorectal cancer(77), Cancer Cells and Metastasis(37), Glioma Diagnosis and Treatment(34), Lung Cancer Treatments and Mutations(32)

Publications435 total

Abstract No. 133 Complete Pathologic Necrosis using Bridging Locoregional Therapy Impacting Long-Term Outcomes in Patients with Hepatocellular Carcinoma Post Liver Transplantation
Journal of Vascular and Interventional Radiology·2025Open Access
Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression
Journal for ImmunoTherapy of Cancer·2024· 5 citedOpen Access
Abstract PO1-14-11: Different molecular processes are associated with recurrence in the clinical high- genomic low risk (cH/gL) and clinical low- genomic high risk (cL/gH) groups of the MINDACT clinical trial
Cancer Research·2024
Targeting of the NOX1/ADAM17 Enzymatic Complex Regulates Soluble MCAM-Dependent Pro-Tumorigenic Activity in Colorectal Cancer
Biomedicines·2023· 1 citedOpen Access
Clonal expansion of intra‐epithelial T cells in breast cancer revealed by spatial transcriptomics
International Journal of Cancer·2023· 11 citedOpen Access
Supplementary Methods, Figure Legends 1-5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Table 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Table 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 3 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Data from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 4 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 4 cont. from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 4 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 3 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Table 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
Supplementary Figure 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
2023Open Access
page 1 of 22Next →

Frequent Co-authors

Sabine Tejpar(12), Martine Piccart(10), Christos Sotiriou(9), Jonas Bergh(8), Pierre Farmer(7), Fred T. Bosman(7), Edoardo Missiaglia(6), Pratyaksha Wirapati(6), Benjamin Haibe‐Kains(6), Christine Desmedt(6), Sherene Loi(5), Denis Larsimont(5), Fátima Cardoso(5), Marc Buyse(5), Vlad Popovici(5), Daniel R. Goldstein(5), Monika E. Hegi(5), Justin Guinney(4), Charlotte Soneson(4), Eric Van Cutsem(4)